Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2010 - 2026)

Rigel Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $89.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 34.31% year-over-year to $89.5 million; the TTM figure through Mar 2026 stood at $89.5 million (up 34.31% YoY), while the FY2025 annual figure was $99.2 million, up 56.77% from the prior year.
• Total Current Liabilities was $89.5 million for Q1 2026 at Rigel Pharmaceuticals, down from $99.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $99.2 million in Q4 2025 to a low of $44.0 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $64.9 million across 5 years, with a median of $59.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities declined 23.14% in 2023, then jumped 73.81% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $65.2 million in 2022, then declined by 18.32% to $53.3 million in 2023, then grew by 18.83% to $63.3 million in 2024, then jumped by 56.77% to $99.2 million in 2025, then decreased by 9.82% to $89.5 million in 2026.
• The last three Total Current Liabilities figures came in at $89.5 million (Q1 2026), $99.2 million (Q4 2025), and $94.4 million (Q3 2025), per Business Quant data.